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Edited by Laszlo NagyAbstract In cardiac cells the eﬀects of n  3 PUFAs on the
whole genome are still unknown despite their recognized cardio-
protective eﬀects and ability to modulate gene expression. We
have evaluated the eﬀects of n  3 PUFAs supplementation on
the global gene expression proﬁle in cultured neonatal rat cardio-
myocytes, detecting many genes related to lipid transport and
metabolism among the upregulated ones. Many of the downreg-
ulated genes appeared related to inﬂammation, cell growth,
extracellular and cardiac matrix remodelling, calcium move-
ments and ROS generation. Our data allow to speculate that
the cardioprotective eﬀect of n  3 PUFAs is related to a direct
modulation of genes in cardiac cells.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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N  3 PUFAs, namely eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), are believed to have a protective
action against cardiovascular diseases (CVDs), particularly
coronary heart diseases, and ﬁsh oil feeding has been associ-
ated to reduced mortality in several studies [1].
N  3 PUFAs play a key role in the prevention or progres-
sion of human diseases by diﬀerent mechanisms, i.e. by modu-Abbreviations: ALA, a linolenic acid; ADRP, adipose diﬀerentiation-
related protein; CH, cardiac hypertrophy; CVD, cardiovascular dis-
eases; DECR1, 2,4-dyenoylCoA reductase 1; DHA, docosahexaenoic
acid; DPT, dermatopontin; ECH1, enoylCoA hydratase 1; ECM, ex-
tracellular and cardiac matrix; EPA, eicosapentaenoic acid; GAPDH,
glyceraldehyde-3-phosphate-dehydrogenase; HF, heart failure; HM-
GCS2, 3-hydroxy-3-metylglutarylCoA synthase 2; Il-6, interleukin-6;
MBEI, model based expression index; MI, myocardial infarction; M-
MP12, matrix metalloproteinase 12; NEFA, non-esteriﬁed fatty acid;
NFkB, nuclear factor-kappa B; PPAR, peroxisome proliferator acti-
vated receptor; PUFA, polyunsaturated fatty acid; ROS, reactive ox-
ygen species; SAM, signiﬁcance analysis of microarrays; STAR,
steroidogenic acute regulatory protein; STAT3, signal transducer and
activator of transcription 3; TIMP, tissue inhibitors of matrix metallo-
proteinase; TNFa, tumor necrosis factor-alpha
*Corresponding author. Fax: +39 051 2091235.
E-mail address: alessandra.bordoni@unibo.it (A. Bordoni).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.01.070lating membrane lipid composition and by aﬀecting metabolic
and signal-transduction pathways [2]; nowadays, a direct con-
trol of gene expression by PUFAs has been demonstrated [3].
Many studies have been addressed to the understanding of the
molecular mechanisms underlying the eﬀects of PUFAs on
gene expression in the liver [3], but little is known about the
heart, and the eﬀects of EPA and DHA on the whole genome
have never been investigated in cardiomyocytes. Nowadays,
novel techniques, such as DNA microarrays, enable the study
of cardiomyocyte gene expression changes in response to
PUFA in a global way. Using this novel approach, we have
evaluated the eﬀects of EPA and DHA supplementation on
the global gene expression proﬁle in cultured neonatal rat
cardiomyocytes.
Although mammals are able to synthesise EPA and DHA
from a linolenic acid (ALA), the lack of eﬀectiveness of the
precursor fatty acid in CVD has been recently reviewed by
Wang et al. [4], so we focused our attention on the two n  3
PUFAs which appear to prevent cardiac diseases.2. Materials and methods
2.1. Materials
Ham F10 media, fetal calf serum (FCS), horse serum (HS), propi-
dium iodide, EPA and DHA were from Sigma (St. Louis, MO,
USA); rat oligo array G4130A and Low RNA input ﬂuorescent linear
ampliﬁcation kit were from Agilent Technologies (Palo Alto, CA,
USA); RNAeasy protect miny kit was from Qiagen (Milan, Italy),
Cy3-CTP and Cy5-CTP were from Perkin Elmer (Milan, Italy); prim-
ers were custom synthesized by Proligo (Sigma-Aldrich, Milan, Italy)
and TIB MolBiol (Roche Diagnostics, Milan, Italy); Superscript II
RT was from Invitrogen (Milano, Italy).
2.2. Methods
2.2.1. Cell cultures. Primary cultures of cardiomyocytes were
obtained from the ventricles of newbornWistar rats according to Yagev
et al. [5]. The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NHI Publication No. 85–23, 5 revised 1996). To obtain pure
cultures avoiding the presence of ﬁbroblasts, cells were pre-plated twice
before the ﬁnal seeding, and the absence of cells other than cardiomyo-
cytes veriﬁed microscopically. After 48 h in control medium (Ham F10
plus 10% FCS and 10%HS), some cells were shifted to a 60 lMEPA or
a 60 lM DHA supplemented medium. Fatty acids were dissolved in
ethanol, and control medium was added with the same volume of eth-
anol (0.01% v/v). Media were changed every 48 h; on day 8 from seed-
ing, after 6 day exposure to n  3 PUFAs and at complete conﬂuence,
cardiomyocytes were washed three times with 0.9% NaCl and scraped
oﬀ.blished by Elsevier B.V. All rights reserved.
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ids were extracted [6] and separated by thin layer chromatography.
Spots corresponding to phospholipids were scraped oﬀ; fatty acids
were methyl-esteriﬁed and gas-chromatographed [7].
2.2.2. Cell cycle and apoptosis. Cells were seeded in 24-well plates at
a concentration of 200000/well in complete medium. Some cells were
shifted to EPA- or DHA-containing medium 48 h after seeding.
Two–four replicates were performed for each time point. Viable cells
were counted by trypan blue dye exclusion each day for the following
6 days. Apoptosis and cell cycle analysis were performed by cytoﬂuo-
rimetric detection with a FACS Calibur Cytometer (Becton Dickinson,
Mansﬁeld, MA) [8] after staining with propidium iodide. Cell cycle dis-
tribution was calculated using ModFit software (Verify Software
House, Inc., Mansﬁeld, MA).
2.2.3. Microarray analysis. Cells were scraped oﬀ in ice cold PBS,
treated with RNAlater and homogenized. Total RNA was extracted
(RNAeasy Protect mini kit) and analysed on both a spectrophotometer
and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Only samples with 28S/18S ratio > 2.0 and no evidence of ribosomal
degradation were included. The cRNA was generated by in vitro tran-
scription (Low RNA input ﬂuorescent linear ampliﬁcation kit),
labelled with Cy3-CTP or Cy5-CTP, and hybridized to 22 K-gene
arrays (Agilent Rat oligo array G4130A) containing sequences repre-
senting over 20000 well-characterized rat transcripts. Direct compari-
sons were performed between n  3 PUFAs supplemented cells versus
unsupplemented ones (controls), and each analysis was dye-swapped.
Data analysis was performed using R and Bioconductor packages
(www.bioconductor.org). Red and green signals were background-sub-
tracted and normalized (Lowess smoother). The whole dataset was ﬁl-
tered to exclude genes poorly expressed in all the samples or not
varying (coeﬃcient of variation of at least 2), thus leading to a list
of 7110 genes.
To compare control and n  3 PUFA supplemented cardiomyo-
cytes, SAM (signiﬁcance analysis of microarrays) algorithm was used,
minimizing potential false positive genes (<3%). Hierarchical clustering
was performed using Manhattan distance and complete linkage.
2.2.4. Real time PCR. Validation of selected genes was performed
by quantitative real-time PCR with a 5700 Applied Biosystems (Ap-
plied Biosystems, Foster City, CA) apparatus. One lg of total RNA
was retrotranscribed using random hexamers and Superscript II RT.
Speciﬁc primer pairs (Table 1) were chosen by Primer Express 2.0 (Ap-
plied Biosystems, Foster City, CA). Gene expression was normalized
to the housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH).Table 1
Sequences of speciﬁc primer pairs used for real-time PCR
Gene name Direc
HMGCS2 (3-hydroxy-3-metylglutaryl CoA synthase 2) CGCA
ECH1 (enoylCoA hydratase 1) AATT
STAR (steroidogenic acute regulatory protein) GGCC
DECR1 (2,4-dyenoylCoA reductase 1) GGCG
MMP12 (matrix metalloproteinase 12) CATT
DPT (dermatopontin) AGGC
GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) CTTG
Table 2
Upregulated genes in n  3 PUFA supplemented cardiomyocytes with respe
GenBank UniGene Gene name
NM_173094 Rn.29594 3-Hydroxy-3-metylglutaryl C
NM_013200 Rn.6028 Carnitine palmitoyltransfera
NM_022594 Rn.6148 EnoylCoA hydratase 1, pero
AA899721 Rn.37524 Mitochondrial acylCoA thio
BI285616 Rn.101967 Adipose diﬀerentiation-relate
NM_031558 Rn.11399 Steroidogenic acute regulato
NM_057197 Rn.2854 2,4-dyenoylCoA reductase 1
NM_145090 Rn.11219 ADP-ribosylation factor GT
Upregulated genes are identiﬁed by Genbank and Unigene code. Diﬀerenti
logarithm of the expression ratio) between PUFA-treated and untreated cell2.2.5. PPAR activation. The activation of PPARa and b/d by n  3
PUFAs was determined by an immunosorbent assay (ELISA) utilizing
PPARa and b/d transcription factor assay kits (Cayman Chemicals,
USA). Nuclear extracts were prepared from cardiomyocytes by diﬀer-
ential centrifugation according to Wright et al. [9] and the assay per-
formed following the manufacturer’s instruction.3. Results
In cardiomyocytes, supplemented n  3 PUFAs were incor-
porated into phospholipids, and their amount increased about
10-fold in comparison with control cells (data not shown).
In mammals EPA can be converted into DHA and DHA
can be retro converted into EPA [10], both pathways taking
place mainly in liver peroxisomes. Consequently, when accord-
ing to clinical practice ﬁsh oil or supplements are administered,
it is diﬃcult to assess which eﬀects are due to EPA and which
to DHA, since they are inter convertible. Cultured cardiomyo-
cytes are able to synthesise DHA from EPA [11], but no data
are reported in the literature about the retro conversion of
DHA in cardiac cells. So the rate of the inter conversion
between EPA and DHA could be diﬀerent in cultured cardio-
myocytes and in the whole animal, this being an interfering
factor in the interpretation of the results. To avoid it, we sup-
plemented cells with 60 lM EPA or 60 lM DHA and per-
formed separated microarray analysis. Then, we compared
results obtained with the two diﬀerent supplementations and
considered as modulated only genes upregulated or downregu-
lated in a signiﬁcant way by both the fatty acids. In this way,
we obtained results independent by the rate of inter conversion
between the two fatty acids. With the same aim, in RT-PCR,
cell growth, apoptosis and PPAR activation experiments we
considered data from EPA and DHA supplemented cardio-
myocytes all together.
The expression of 122 cDNA was signiﬁcantly altered in
cardiomyocytes grown in the n  3 PUFAs enriched mediumt Reverse
TGTCCCCTGAGGAATT CCAAGTGCCTGGGAAGAGGT
CACGGAGGCTGCATTG GCAGCGTTCCTACATCAGCA
TTGGGCATACTCAACA CAGCACCTCCAGTCGGAACA
TGGAAGCCATGAATAA TCAAATTTTCCAGTCGGGTCC
CTCTGGGCTTCCCTGC TGAGTTCCTGCCTCACATCGT
CACTACGGCGAAGAC CCGGCACATTATGAACTTCCA
TGCAGTGCCAGCCTC CAAGAGAAGGCAGCCCTGGTA
ct to controls
Fold change LogR
oA synthase 2 2.19 1.13
se 1b 2.03 1.02
xisomal 1.78 0.83
esterase 1 1.59 0.67
d protein 1.53 0.61
ry protein 1.51 0.59
1.38 0.46
Pase activating protein 1 1.24 0.31
al expression is shown as fold change and log ratio (LogR; base-two
s.
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ﬁed genes, 2 EST, 7 unknown sequences) and 105 were down-
regulated (39 identiﬁed genes, 30 EST, 36 unknown
sequences) relative to controls (false discovery rate <3%). Data
on gene expression are available on the GEO website (http://
www.ncbi.nlm.nih.gov/geo/) with the accession number
GSE4327. Identiﬁed upregulated genes are reported in Table
2; identiﬁed downregulated genes, listed according to molecular
function, are reported in Table 3. To conﬁrm results we per-
formed real-time PCR analysis of some interesting upregulated
(HMGCS2, STAR, ECH1, DECR1) and downregulated genes
(DPT, MMP12), showing that microarray results are reliableTable 3
Downregulated genes in n  3 PUFA supplemented cardiomyocytes with re
GenBank UniGene Gene Name
Related to lipid metabolism
NM_031841 Rn.83595 Scd2; stearoyl-Coenzyme A desaturase 2
Related to inﬂammation
NM_053843 Rn.107323 Fcgr3; Fc receptor, IgG, low aﬃnity III
NM_023025 Rn.44992 Cyp2j4; CYP2J4
NM_012589 Rn.9873 Il6; interleukin 6
X73371 Rn.33323 Fcgr2b; Fc receptor, IgG, low aﬃnity IIb
NM_138900 Rn.4037 C1s; complement component 1, s subcompo
NM_012870 Rn.9792 Tnfrsf11b; tumor necrosis factor receptor su
AF159103 Rn.92334 Tnﬁp6; tumor necrosis factor induced prote
BI289859 Rn.8807 Ignt; I-branching beta-1,6-acetylglucosaminy
AA800318 Rn.100285 Serping1; serine (or cysteine) proteinase inhi
NM_080698 Rn.8778 Fmod; ﬁbromodulin
AA858732 Rn.2283 Lyz; lysozyme
Related to cell survival and ECM remodelling
BI275292 Rn.9048 Agpt2; angiopoietin-2
NM_031050 Rn.3087 Lum; lumican
BM389281 Rn.30828 Scgf; stem cell growth factor
NM_017066 Rn.1653 Ptn; pleiotrophin
NM_022177 Rn.54439 Cxcl12; chemokine (C-X-C motif) ligand 12
CB544481 Rn.2379 Mgp; matrix Gla protein
NM_053963 Rn.33193 Mmp12; matrix metalloproteinase 12
BM386671 Rn.8396 Dpt; dermatopontin
Related to cell proliferation, cell cycle and regulation of transcription
NM_031335 Rn.28212 Polr2f; polymerase II
NM_017029 Rn.10971 Nef3; neuroﬁlament 3, medium
AI103327 Rn.14867 Tcf19; transcription factor 19
U17565 Rn.33226 Mcmd6; mini chromosome maintenance deﬁ
AA858882 Rn.82737 Zfp36; zinc ﬁnger protein 36
NM_057144 Rn.11345 Csrp3; cysteine-rich protein 3
AI012106 Rn.19481 Bteb1; basic transcription element binding p
NM_138856 Rn.53644 Gs3; putative regulation protein GS3
NM_019282 Rn.42929 Cktsf1b1; cysteine knot superfamily 1, BMP
AA964489 Rn.92160 Ceacam10; CEA-related cell adhesion molec
Related to Ca2+ movements and cardiac contractility
NM_131914 Rn.81070 Cav2; caveolin 2
NM_022005 Rn.839 Fxyd6; FXYD domain-containing ion trans
Related to ROS production
AI137330 Rn.98491 Cybb; endothelial type gp91-phox gene
Other functions
BM385476 Rn.32168 Damp1; DAMP-1 protein
AI230347 Rn.7233 Ns5atp9; Ns5atp9 protein
NM_133594 Rn.103348 Sumo2; SMT3 suppressor of mif two 3 hom
NM_145093 Rn.38451 Aard; A5D3 protein
NM_053591 Rn.6051 Dpep1; dipeptidase 1 (renal)
Downregulated genes are grouped according to their function and identiﬁed
Diﬀerential expression is shown as fold change and log ratio (LogR; base
untreated cells.and that PUFA supplementation is able to induce substantial
changes in the gene expression proﬁle of cardiac cells (Fig. 1).
Upregulation of genes by PUFAs is considered mainly due
to the activation of PPARs. As shown in Fig. 2A, the expres-
sion of the three PPAR genes, reported as the mean normal-
ized ﬂuorescence level in the four microarray experiments
performed, was not inﬂuenced by PUFA supplementation,
and the ﬂuorescence level suggested a low expression in all
samples. Regarding PPAR activation, no diﬀerences were
detected in PPARa between control and supplemented cardio-
myocytes (data not shown), while PPARb/d appeared signiﬁ-
cantly activated in n  3 PUFAs supplemented cells (Fig. 2B).spect to controls
Fold change LogR
0.77 0.37
0.83 0.27
0.82 0.29
0.82 0.29
0.81 0.30
nent 0.80 0.33
perfamily, member 11b 0.78 0.35
in 6 0.76 0.39
ltransferase 0.76 0.39
bitor, clade G (C1 inhibitor), member 1 0.71 0.49
0.71 0.50
0.64 0.64
0.86 0.22
0.84 0.26
0.80 0.33
0.75 0.41
0.72 0.48
0.65 0.62
0.59 0.76
0.51 0.96
0.85 0.23
0.83 0.27
0.82 0.28
cient 6 0.81 0.31
0.78 0.35
0.77 0.38
rotein 1 0.76 0.39
0.71 0.50
antagonist 1 0.66 0.59
ule 10 0.60 0.73
0.82 0.29
port regulator 6 0.76 0.39
0.61 0.71
0.81 0.30
0.80 0.32
olog 2 0.75 0.42
0.73 0.45
0.71 0.50
by Genbank and Unigene code.
-two logarithm of the expression ratio) between PUFA-treated and
Fig. 1. Diﬀerential expression of selected genes in control and n  3 PUFA supplemented cardiomyocytes by real-time PCR. Data are means ± S.D.
of the results obtained in both EPA and DHA supplemented cardiomyocytes (2–4 biological replicates and 2–4 technical replicates in each condition).
The expression of every gene was normalized to GAPDH expression. Signiﬁcance: Students’ t test (*P < 0.05; **P < 0.01).
Fig. 2. Expression and activation of PPARs in control and supplemented cardiomyocytes. Data are means ± S.D. of results obtained in both EPA
and DHA supplemented cardiomyocytes. (A) Level of expression of PPARa, b/d, and c in control and n  3 PUFA supplemented cardiomyocytes.
The expression of the three PPAR genes is shown as the mean normalized ﬂuorescence level in the four microarray experiments performed. (B)
Activation of PPAR b/d in control and n  3 PUFA supplemented cardiomyocytes. Signiﬁcance: Students’ t test (***P < 0.001).
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PUFAs in cardiomyocyte survival and proliferation, we stud-
ied the eﬀects of the supplementation on these biological pro-
cesses. PUFA-supplemented cardiomyocytes showed a modest
increase in cell growth at late time points (P < 0.05 after 6 days
in n  3 PUFA supplemented media, Fig. 3A), and no signiﬁ-cant alteration in cell cycle distribution (data not shown).
PUFA supplementation signiﬁcantly protected cardiomyo-
cytes from apoptosis (30% apoptosis inhibition already at early
time points; Fig. 3B); pictures taken after 1 and 4 days of sup-
plementation conﬁrmed the increase in cell survival due to
n  3 PUFAs (Fig. 3C and D).
Fig. 3. Eﬀects of PUFA supplementation on cell morphology, growth and apoptosis. Data are means ± S.D. of results obtained in both EPA and
DHA supplemented cardiomyocytes. (A) Growth percentage over control of PUFA-treated cells. Each point is the mean ± S.E.M. of 4–8 replicates.
Signiﬁcance: Students’ t test (*P < 0.05). (B) Percentage of apoptosis inhibition by PUFA supplementation: each bar is the mean ± S.E.M. of two
replicates. Signiﬁcance: Students’ t test (*P < 0.05). (C) and (D) Microscopic observation of cell growth; pictures taken after 1 day (C) and 4 days (D)
of supplementation with EPA or DHA.
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In cardiac cells n  3 PUFA supplementation caused the
induction of several genes encoding proteins involved in lipid
transport and metabolism, leading to a signiﬁcant enrichment
of transcripts belonging to Gene Ontology categories ‘‘lipid
metabolism’’, ‘‘fatty acid metabolism’’ and ‘‘lipid transport’’
(P-value> 0.01). Particularly, the upregulation of adipose dif-
ferentiation-related protein (ADRP), CPT1b and ECH1 genes
possibly explains the pleiotropic eﬀect reported for n  3 PU-
FAs in the heart, which preferably uses fatty acids as an energy
source. ADRP, CPT1b and ECH1 genes, as many genes in-
volved in cardiac energy metabolism, are PPAR-regulated;
the observed upregulation of the gene encoding for acylCoA
thioesterase, responsible for the cleavage of acylCoAs to the
corresponding non-esteriﬁed fatty acids (NEFAs) and CoASH
[12], may facilitate the n  3 PUFA mediated activation of
PPARs, since NEFAs are preferential ligands of these nuclear
receptors.
PPARa is expressed primarily in tissues that have a high
level of fatty acid catabolism such as heart, while PPARb/d
is ubiquitously expressed [13]. Recently, Gilde et al. [14], using
neonatal rat cardiomyocytes as well as the embryonic rat
heart-derived H9c2 cells, clearly demonstrated that PPARb/d
is the predominant PPAR subtype in cardiac cells and plays
a prominent role in the regulation of cardiac lipid metabolism,
suggesting that PPAR b/d may play an important role in car-
diac disease. In our study PPARa was not activated by EPA or
DHA, while PPAR b/d was signiﬁcantly activated. This is in
agreement with Gilde et al. [14], who demonstrated that
PPARb/d was fatty acid inducible and activated the expression
of PPARa target genes involved in fatty acid utilization in car-
diac myocytes, suggesting that PPARa and PPARb/d shared
similar functions in cardiac cells regarding cardiac fatty acidmetabolism. More recently Planavila et al. [15] demonstrated
that PPARb/d activation inhibits phenylephrine-induced car-
diomyocyte hypertrophy in neonatal rat ventricular cardio-
myocytes. PPARb/d activation also inhibits LPS-induced
NF-jB activation through a mechanism that may involve
enhanced protein–protein interaction between this PPAR sub-
type and the p65 subunit of NF-jB. These data indicate that
inhibition of the NF-jB signaling pathway may be the under-
lying mechanism responsible for the inhibition of cardiomyo-
cyte growth. Regarding PPARc, it has been initially reported
that it has a restricted pattern of expression, mainly in white
and brown adipose tissues, whereas other tissues such as heart
contain limited amounts. Very recently Ding et al. [16] indi-
cates not only that PPARd is expressed in cardiomyocytes,
but also that in these cells it is a negative regulator of TNFa
production via suppressing the NF-jB pathway. Our data
about PPARc expression are in agreement with Ding, and
although further studies about the activity of n  3 PUFAs
as PPARc ligands are needed, it is possible to speculate about
the role of this transcription factor in EPA and DHA anti-
inﬂammatory activity in the heart.
Diﬀerently from liver, in cardiomyocytes, n  3 PUFAs did
not downregulate genes involved in glucose metabolism and
fatty acid synthesis, apart from stearoylCoA desaturase 2.
Unexpectedly, many genes downregulated by n  3 PUFAs
were related to cellular pathways controlling inﬂammation
response, cardiac remodelling and angiogenesis, and apoptosis.
Chronic induction of inﬂammatory cytokines, such as TNFa
or interleukin-6 (Il-6), and chronic inﬂammation are associated
with the onset and progression of cardiac hypertrophy (CH)
[17] and myocardial infarction (MI) [18]. N  3 PUFAs are
considered potent anti-inﬂammatory agents [19], and their
anti-inﬂammatory eﬀects may be due to the inhibition of
928 A. Bordoni et al. / FEBS Letters 581 (2007) 923–929NFjB and STAT3 activation via PPAR activation [15,20,21].
Although further studies are needed in cardiomyocytes during
cytokine-induced inﬂammation before drawing ﬁnal conclu-
sion, in the light of the downregulation of inﬂammatory genes
our data conﬁrm the potential anti inﬂammatory role of n  3
PUFAs in cardiac cells.
Both CH and MI are characterised by cardiac and extracel-
lular matrix (ECM) remodelling. Increased collagen synthesis
causes ﬁbrosis; metalloproteinases break down collagen, with
their actions restricted by TIMPs (tissue inhibitors of matrix
metalloproteinases) [22]. Once the metalloproteinase-TIMP
balance is upset in favour of increased metalloproteinase activ-
ity, collagen crosslinks degenerate so that the hypertrophied
left ventricle begins to dilate [23]. The observed downregula-
tion of matrix metalloproteinase 12 in n  3 PUFA cells could
be supposed to contribute to the counteraction of ﬁbrosis.
Since microarray data indicated a modulation of genes
related to cell proliferation, cell cycle and regulation of tran-
scription, some experiments were performed in order to verify
the eﬀects of PUFA supplementation on these biological pro-
cesses. After an initial inhibiting eﬀect, PUFA supplemented
cardiomyocytes showed a modest increase in cell growth at late
time points, without any signiﬁcantly alteration in cell cycle
distribution. The eﬀect on cell growth could be explained by
a signiﬁcant protection from apoptosis by PUFA treatment.
Apoptosis of cardiomyocytes plays a pivotal role in the pro-
gression of CH and MI toward heart failure (HF) [24,25], so
the decrease in programmed cell death could be one of the pro-
tective mechanisms of n  3 PUFAs. According to Shimojo
et al. [26], we did not ﬁnd any modiﬁcation in gene expression
of three important molecules related to apoptosis (caspase-3,
Bax and Bcl-2); notwithstanding, since the execution of the
apoptotic program entails complex interactions between and
execution of multiple molecular subprograms, and in the light
of our data, a counteraction of programmed cell death by
n  3 PUFAs has to be carefully considered.
Consonant with overall knowledge, high rates of ROS pro-
duction [27] and changes in calcium homeostasis are strictly
related to CH and MI, too. N  3 PUFAs downregulated
the gene encoding for GP91phox, the subunit responsible for
the catalytic activity of NADPH-oxidase, which is reported
to be the main source of ROS production during CH and
MI [28], and the gene encoding for caveolin-2, therefore inter-
fering with the biogenesis of caveolae. Recently Morris et al.
[29] demonstrated that a1-adrenergic receptor signalling,
which activation can initiate arrhythmogenesis, is localized to
caveolae in neonatal rat cardiomyocytes.
All together, our microarray data suggest that n  3 PUFAs
regulate many genes involved in CH and infarction. As a con-
ﬁrmation, analysing published microarray datasets obtained in
a rat model of CH [30] and in a murine model of MI [31] and
comparing them to our data it appears clear that genes upreg-
ulated during MI or CH are downregulated by n  3 PUFA
and vice versa.
Evidence from epidemiological and randomized controlled
trials shows beneﬁcial eﬀects of n  3 PUFAs from ﬁsh sources
on CVD, especially in patients with preexisting CVD. These
data have led the American Heart Association Dietary Guide-
lines committee to recommend to the general population the
consumption of at least two servings of ﬁsh per week. A recent
systematic review of the literature on the eﬀects of n  3 PU-
FAs on cardiovascular disease outcomes and adverse eventsindicate that, in secondary prevention, most trials reported
that ﬁsh oil signiﬁcantly reduced all-cause mortality, MI, car-
diac and sudden death, or stroke [4]. In primary prevention,
most cohort studies reported that ﬁsh consumption was asso-
ciated with lower rates of all-cause mortality and adverse car-
diac outcomes, while the eﬀects on stroke were inconsistent [4].
In this scenario, and apart from clinical data, the debate on
n  3 PUFA mechanism of action is still open. In this work,
utilizing high throughput technologies, we analysed the molec-
ular events due to n  3 PUFA supplementation in a global
way, reporting for the ﬁrst time data about the modulation
of gene expression proﬁle by these fatty acids in cardiomyo-
cytes. Our data conﬁrm the possibility that the mechanism of
action of n  3 PUFAs is not only related to the prevention
of the metabolic syndrome or to the anti arrhythmic eﬀect
due to stabilization of cell membrane, but also to direct eﬀects
on cardiac cell genome, and provide a new putative link
between n  3 PUFA supplementation and prevention of myo-
cardial dysfunctions.
Further studies are needed to elucidate the molecular eﬀects
of n  3 PUFAs, as well as to verify which nuclear receptors
among the many having fatty acids as putative ligands [32],
are involved in cardiac cells, but the global vision given by
our results may be important for addressing researches toward
speciﬁc pathways.
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